Home > Publications database > A case-cohort study of the association between adiponectin and mortality in EPIC-Heidelberg: NT-proBNP may explain the adiponectin paradox. > print

001     265122
005     20240229154916.0
024 7 _ |a 10.1016/j.numecd.2023.01.014
|2 doi
024 7 _ |a pmid:36740561
|2 pmid
024 7 _ |a 0939-4753
|2 ISSN
024 7 _ |a 1590-3729
|2 ISSN
024 7 _ |a altmetric:149030950
|2 altmetric
037 _ _ |a DKFZ-2023-00284
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Mukama, Trasias
|0 P:(DE-He78)ef3f7c40c2c68936a43baab29d559371
|b 0
|e First author
|u dkfz
245 _ _ |a A case-cohort study of the association between adiponectin and mortality in EPIC-Heidelberg: NT-proBNP may explain the adiponectin paradox.
260 _ _ |a Amsterdam [u.a.]
|c 2023
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2023-01-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1681886579_17225
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020#LA:C020# / 2023 Apr;33(4):853-863
520 _ _ |a NT-proBNP has been hypothesized as a possible explanation for the paradoxical association between adiponectin and cardiovascular and all-cause mortality. We examined the heterogeneities by NT-proBNP, sex, BMI, smoking status, hypertension and diabetes status in the association between adiponectin and cardiovascular disease risk and mortality.We used a case-cohort design nested within the EPIC-Heidelberg cohort, including 1387 incident cases of myocardial infarction or stroke, 582 deaths from cardiovascular causes and 2352 total deaths. We estimated hazard ratios for the association between 1SD increase in log-transformed total adiponectin levels and cardiovascular disease risk, cardiovascular mortality and mortality using Prentice-weighted Cox-proportional hazard models and assessed heterogeneity of the associations across strata of covariates. Overall, adiponectin was significantly associated with all-cause mortality [HR = 1.09, 95% CI: 1.03-1.16, p = 0.004]. The association with cardiovascular mortality did not reach statistical significance [1.10 (0.99-1.37), p = 0.073]. There was significant heterogeneity by NT-proBNP in the association between total adiponectin and all-cause mortality (phet = 0.019) such that significant increase in hazards of mortality were restricted to participants in the highest tertile of NT-proBNP. Among these participants, adiponectin showed a dose-response relationship with total mortality such that; compared to participants in the lowest quintile, those in the third, fourth and fifth were at 1.22 (0.87-1.70), 1.50 (1.07-2.11), and 1.59 (1.15-2.21) higher hazards of mortality respectively.Significant association between adiponectin and mortality was only observed in the context of high NT-proBNP. Our findings provide further support for hypothesis that NT-proBNP may explain the adiponectin paradox.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
542 _ _ |i 2023-01-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2023-01-23
|2 Crossref
|u http://creativecommons.org/licenses/by-nc-nd/4.0/
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Adiponectin paradox
|2 Other
650 _ 7 |a All-cause mortality
|2 Other
650 _ 7 |a Cardiovascular disease risk
|2 Other
650 _ 7 |a Cardiovascular mortality
|2 Other
650 _ 7 |a NT-proBNP
|2 Other
700 1 _ |a Johnson, Theron
|0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
|b 1
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 2
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 3
|e Last author
|u dkfz
773 1 8 |a 10.1016/j.numecd.2023.01.014
|b Elsevier BV
|d 2023-01-01
|3 journal-article
|2 Crossref
|t Nutrition, Metabolism and Cardiovascular Diseases
|y 2023
|x 0939-4753
773 _ _ |a 10.1016/j.numecd.2023.01.014
|g p. S093947532300025X
|0 PERI:(DE-600)2050914-5
|n 4
|p 853-863
|t Nutrition, metabolism and cardiovascular diseases
|v 33
|y 2023
|x 0939-4753
909 C O |p VDB
|o oai:inrepo02.dkfz.de:265122
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)ef3f7c40c2c68936a43baab29d559371
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUTR METAB CARDIOVAS : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-24
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1074/jbc.270.45.26746
|9 -- missing cx lookup --
|1 Scherer
|p 26746 -
|2 Crossref
|t J Biol Chem
|v 270
|y 1995
999 C 5 |a 10.1371/journal.pone.0136819
|1 Iannitti
|9 -- missing cx lookup --
|2 Crossref
|t PLoS One
|v 10
|y 2015
999 C 5 |a 10.1155/2018/4627842
|1 Li
|9 -- missing cx lookup --
|2 Crossref
|t J Diabetes Res
|v 2018
|y 2018
999 C 5 |a 10.1371/journal.pone.0210654
|1 Potenza
|9 -- missing cx lookup --
|2 Crossref
|t PLoS One
|v 14
|y 2019
999 C 5 |a 10.1210/jc.2003-030214
|9 -- missing cx lookup --
|1 Gavrila
|p 4823 -
|2 Crossref
|t J Clin Endocrinol Metab
|v 88
|y 2003
999 C 5 |a 10.1210/jc.2006-0836
|9 -- missing cx lookup --
|1 Pilz
|p 4277 -
|2 Crossref
|t J Clin Endocrinol Metab
|v 91
|y 2006
999 C 5 |a 10.1007/s00125-003-1074-z
|9 -- missing cx lookup --
|1 Cnop
|p 459 -
|2 Crossref
|t Diabetologia
|v 46
|y 2003
999 C 5 |a 10.1161/01.HYP.0000169444.05588.4c
|9 -- missing cx lookup --
|1 Iwashima
|p 1094 -
|2 Crossref
|t Hypertension
|v 45
|y 2005
999 C 5 |a 10.1038/sj.ijo.0802006
|9 -- missing cx lookup --
|1 Jackson
|p 789 -
|2 Crossref
|t Int J Obes Relat Metab Disord
|v 26
|y 2002
999 C 5 |a 10.7326/0003-4819-149-5-200809020-00005
|9 -- missing cx lookup --
|1 Heidemann
|p 307 -
|2 Crossref
|t Ann Intern Med
|v 149
|y 2008
999 C 5 |a 10.1038/hr.2012.42
|9 -- missing cx lookup --
|1 Chen
|p 843 -
|2 Crossref
|t Hypertens Res
|v 35
|y 2012
999 C 5 |a 10.1111/dom.12905
|9 -- missing cx lookup --
|1 Bergmark
|p 962 -
|2 Crossref
|t Diabetes Obes Metabol
|v 19
|y 2017
999 C 5 |a 10.1210/jc.2018-01501
|9 -- missing cx lookup --
|1 Scarale
|p 1357 -
|2 Crossref
|t J Clin Endocrinol Metab
|v 104
|y 2018
999 C 5 |a 10.1016/j.amjcard.2015.11.067
|9 -- missing cx lookup --
|1 Witberg
|p 574 -
|2 Crossref
|t Am J Cardiol
|v 117
|y 2016
999 C 5 |a 10.1210/jc.2008-1435
|9 -- missing cx lookup --
|1 Sattar
|p 3299 -
|2 Crossref
|t J Clin Endocrinol Metab
|v 93
|y 2008
999 C 5 |a 10.1055/a-1239-4349
|9 -- missing cx lookup --
|1 Francischetti
|p 695 -
|2 Crossref
|t Horm Metab Res
|v 52
|y 2020
999 C 5 |1 Jang
|y 2021
|2 Crossref
|o Jang 2021
999 C 5 |a 10.1007/s10654-021-00828-3
|9 -- missing cx lookup --
|1 Srour
|p 49 -
|2 Crossref
|t Eur J Epidemiol
|v 37
|y 2022
999 C 5 |a 10.1016/j.jacc.2020.11.063
|9 -- missing cx lookup --
|1 Hussain
|p 559 -
|2 Crossref
|t J Am Coll Cardiol
|v 77
|y 2021
999 C 5 |a 10.1016/j.jacc.2009.02.038
|9 -- missing cx lookup --
|1 Tsukamoto
|p 2070 -
|2 Crossref
|t J Am Coll Cardiol
|v 53
|y 2009
999 C 5 |a 10.1161/CIRCULATIONAHA.104.530972
|9 -- missing cx lookup --
|1 Kistorp
|p 1756 -
|2 Crossref
|t Circulation
|v 112
|y 2005
999 C 5 |a 10.2337/dbi17-0016
|9 -- missing cx lookup --
|1 Menzaghi
|p 12 -
|2 Crossref
|t Diabetes
|v 67
|y 2018
999 C 5 |a 10.1097/HJR.0b013e32833b09d9
|9 -- missing cx lookup --
|1 Wannamethee
|p 65 -
|2 Crossref
|t Eur J Cardiovasc Prev Rehabil
|v 18
|y 2011
999 C 5 |a 10.1016/j.atherosclerosis.2011.11.038
|9 -- missing cx lookup --
|1 Beatty
|p 587 -
|2 Crossref
|t Atherosclerosis
|v 220
|y 2012
999 C 5 |a 10.1016/j.cca.2009.07.014
|9 -- missing cx lookup --
|1 Dieplinger
|p 87 -
|2 Crossref
|t Clin Chim Acta
|v 408
|y 2009
999 C 5 |a 10.1038/ki.2009.200
|9 -- missing cx lookup --
|1 Drechsler
|p 567 -
|2 Crossref
|t Kidney Int
|v 76
|y 2009
999 C 5 |a 10.1186/s12933-014-0130-y
|9 -- missing cx lookup --
|1 Menzaghi
|p 130 -
|2 Crossref
|t Cardiovasc Diabetol
|v 13
|y 2014
999 C 5 |a 10.1016/j.ijcard.2015.01.057
|9 -- missing cx lookup --
|1 Choi
|p 91 -
|2 Crossref
|t Int J Cardiol
|v 183
|y 2015
999 C 5 |a 10.1016/j.atherosclerosis.2016.04.028
|9 -- missing cx lookup --
|1 Ortega Moreno
|p 23 -
|2 Crossref
|t Atherosclerosis
|v 250
|y 2016
999 C 5 |a 10.1007/5584_2016_14
|9 -- missing cx lookup --
|1 Delgado
|p 1 -
|2 Crossref
|t Adv Exp Med Biol
|v 934
|y 2016
999 C 5 |a 10.1186/1742-5573-4-15
|9 -- missing cx lookup --
|1 Kulathinal
|p 15 -
|2 Crossref
|t Epidemiol Perspect Innovat
|v 4
|y 2007
999 C 5 |a 10.1186/1471-2288-13-88
|9 -- missing cx lookup --
|1 Xue
|p 88 -
|2 Crossref
|t BMC Med Res Methodol
|v 13
|y 2013
999 C 5 |a 10.2337/dc09-9033
|9 -- missing cx lookup --
|p 1327 -
|2 Crossref
|t Diabetes Care
|v 32
|y 2009
999 C 5 |a 10.1111/obr.12027
|9 -- missing cx lookup --
|1 Kanhai
|p 555 -
|2 Crossref
|t Obes Rev
|v 14
|y 2013
999 C 5 |a 10.1161/CIRCRESAHA.116.308716
|9 -- missing cx lookup --
|1 Borges
|p 491 -
|2 Crossref
|t Circ Res
|v 119
|y 2016
999 C 5 |a 10.1016/S0140-6736(03)13976-1
|9 -- missing cx lookup --
|1 de Lemos
|p 316 -
|2 Crossref
|t Lancet
|v 362
|y 2003
999 C 5 |a 10.1016/j.tem.2017.03.004
|9 -- missing cx lookup --
|1 Wang
|p 519 -
|2 Crossref
|t Trends Endocrinol Metabol
|v 28
|y 2017
999 C 5 |a 10.1016/j.peptides.2021.170664
|1 Christen
|9 -- missing cx lookup --
|2 Crossref
|t Peptides
|v 146
|y 2021
999 C 5 |a 10.1111/bph.13619
|9 -- missing cx lookup --
|1 Woodward
|p 4007 -
|2 Crossref
|t Br J Pharmacol
|v 174
|y 2017
999 C 5 |a 10.3389/fendo.2019.00842
|9 -- missing cx lookup --
|1 Liu
|p 842 -
|2 Crossref
|t Front Endocrinol
|v 10
|y 2019

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21